69154-03-6

Basic information

• Product Name: (+/-)-3-AMINO-HOMOPIPERIDINE
• Synonyms: (+/-)-3-AMINO-HOMOPIPERIDINE;3-AMINO-HOMOPIPERIDINE;HEXAHYDRO-1H-AZEPIN-3-AMINE;AZEPAN-3-YLAMINE;DL-3-AMINO HOMOPIPERIDINE;1H-Azepin-3-amine, hexahydro-;(+/-)-3-Amino-homopiperidine hydrochloride;azepan-3-aMine
• CAS NO: 69154-03-6
• Molecular Formula: C₆H₁₄N₂
• Molecular Weight: 114.19
• EINECS: 1533716-785-6
• Mol File: 69154-03-6.mol

Chemical Properties

• Boiling Point: 180.9 °C at 760 mmHg
• Flash Point: 69.6 °C
• Appearance: /
• Density: 0.893 g/cm³
• Vapor Pressure: 0.875mmHg at 25°C
• Refractive Index: 1.453
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.66±0.40(Predicted)
• CAS DataBase Reference: (+/-)-3-AMINO-HOMOPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (+/-)-3-AMINO-HOMOPIPERIDINE(69154-03-6)
• EPA Substance Registry System: (+/-)-3-AMINO-HOMOPIPERIDINE(69154-03-6)

Safety Data

• Hazardous Substances Data: 69154-03-6(Hazardous Substances Data)

Usage

Uses

Azepan-3-amine is a useful reagent for preparing N-alkylated pyrimidinediones.

InChI:InChI=1/C6H14N2/c7-6-3-1-2-4-8-5-6/h6,8H,1-5,7H2

Upstream product

• 29426-64-0 (R)-α-amino-ε-caprolactam hydrochloride 
• 17929-90-7 3-aminoazepan-2-one 

Downstream Products

• 609789-17-5 1-tert-butoxycarbonyl-3-amino-hexahydroazepine 
• 933056-11-2 1-tert-butoxycarbonyl-3-(phenylamino)hexahydroazepine 
• 933056-12-3 1-tert-butoxycarbonyl-3-[(2-methoxyphenyl)amino]hexahydroazepine 
• 933056-13-4 1-tert-butoxycarbonyl-3-[(2-ethylphenyl)amino]hexahydroazepine 
• 485821-40-7 2-[8-(3-aminoazepan-1-yl)-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-ylmethyl]benzonitrile trifluoroacetate 
• 485821-24-7 8-(3-aminoazepan-1-yl)-7-benzyl-3-methyl-3,7-dihydropurine-2,6-dione trifluoroacetate 
• 485821-44-1 8-(3-aminoazepan-1-yl)-1,3-dimethyl-7-(2-chlorobenzyl)-3,7-dihydropurine-2,6-dione trifluoroacetate 
• 485821-26-9 2-(8-(3-aminoazepan-1-yl)-3-methyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-ylmethyl)benzonitrile trifluoroacetate 
• 485821-38-3 8-(3-aminoazepan-1-yl)-7-(2-bromobenzyl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione trifluoroacetate 
• 485821-16-7 2-(8-(3-aminoazepan-1-yl)-7-(2-chlorobenzyl)-3-methyl-2,6-dioxo-1,2,3,6-tetrahydropurin-1-ylmethyl)benzonitrile trifluoroacetate 
• 485821-29-2 8-(3-aminoazepan-1-yl)-7-(2-bromobenzyl)-3-methyl-3,7-dihydropurine-2,6-dione trifluoroacetate 
• 485821-32-7 8-(3-aminoazepan-1-yl)-7-(2-trifluoromethylbenzyl)-3-methyl-3,7-dihydropurine-2,6-dione trifluoroacetate 
• 485821-35-0 8-(3-aminoazepan-1-yl)-7-(2-methylbenzyl)-3-methyl-3,7-dihydropurine-2,6-dione trifluoroacetate 
• 485821-43-0 8-(3-Amino-azepan-1-yl)-7-(2-chloro-benzyl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione 

Relevant articles and documents

SUCCINATE SALTS OF HETEROCYCLIC DPP-IV INHIBITORS

The present invention relates to therapeutically active and selective hemisuccinate salts of inhibitors of the enzyme DPP-IV of formula (I), pharmaceutical compositions comprising the salts and the use of such salts for and the manufacture of medicaments for treating diseases that are associated with proteins that are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity.

HETEROCYCLIC COMPOUNDS THAT ARE INHIBITORS OF THE ENZYME DPP-IV

The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV of formula I, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins that are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity.

Cyclic amine derivatives and their use as drugs

A compound represented by the general formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1-C6alkyl addition salt thereof, and their medical applications. These compounds inhibit the action of chemokines such as MIP-1α and/or MCP-1 on target cells, and are useful as therapeutic and/or preventative drugs in diseases, such as atheroclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissues.

REMEDIES OR PREVENTIVES FOR DISEASES IN ASSOCIATION WITH CHEMOKINES

This invention provides remedies or prophylactics for diseases in association with chemokines such as MIP-1 α and/or MCP-1. Namely, remedies or prophylactics for diseases in association with the chemokines such as rheumatoid arthritis or nephritis contain

Stereochemical Properties of Copper(II) Complexes of (S)-3-Aminohexahydroazepine. Crystal and Molecular Structure of Bromobiscopper(II) Perchlorate ClO4

A series of copper(II) complexes of (S)-3-aminohexahydroazepine (abbreviated as S-ahaz) were prepared.The molecular structure of bromobiscopper(II) perchlorate, ClO4, was determined using single-crystal X-ray diffraction method.The complex crystallizes is spece group P212121 with a=13.449(6), b=17.411(11), c=7.937(2) Angstroem, and Z=4.The structure was solved by the direct method and refined by the least squares to R value of 0.068 for 1853 unique reflections.The Cu2+ ion has the square-pyramidal five-coordination geometry with four nitrogen atoms as basal donors and a bromide as an apical donor.The structures of other copper(II) complexes of S-ahaz were assigned on the basis of the above X-ray analysis result, together with electronic spectral and conductivity measurements.The complexes having the formula Cu(S-ahaz)2X(ClO4) (X-=Cl-, I-, NCS-, ONO-) were assigned to have square-pyramidal five-coordinated structures.The S-ahaz complexes Cu(S-ahaz)2X2 (X-=Cl-, Br-, NO3-) were also considered to have similar five-coordination geometries, while the complexes Cu(S-ahaz)2X2 (X-=ClO4-, BF4-,) to be four-coordinated in the crystalline state.